Hamilton noted that immune-mediated adverse events (AEs) are the main reason that this is not indicated in patients with a CPS score of less than 10. Based on this, the FDA approved pembrolizumab plus chemotherapy for metastatic TNBC with a CPS score of at least 10. However, in those with a CPS score of at least 10, there was a significant benefit in progression-free survival (PFS) with the addition of pembrolizumab. In the intent-to-treat (ITT) population, there was no significant benefit, and this was the same in the CPS cutoff of 1 or greater. In that trial, three-quarters of the patients had programmed death-ligand 1 (PD-L1) expression however, with a more stringent cutoff of a combined positive score (CPS) of at least 10, that number fell to 35% to 40%. For example, the KEYNOTE 355 trial of pembrolizumab in first-line TNBC provided insight into both the setting and metastatic site, as well as how much these considerations matter, according to Hamilton. Hamilton, MD, in a session at the 2023 Community Oncology Alliance (COA) meeting.ĭrugs such as pembrolizumab, sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) all have growing bodies of evidence illustrating which patients are most likely to benefit and in which settings. Triple-negative breast cancer (TNBC) has long presented treatment challenges, but evolving literature and new data show significant promise for this patient population, according to presenter Erika P.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |